Latest Breaking News On - Onxeo sa euronext - Page 4 : comparemela.com

Onxeo S A : Onxeo: Report on the Extraordinary General Meeting of February 6, 2023

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor

France generalArthur rouillOnis onxeoNicolas fossiezOnxeo sa euronextSchwierige zeitenCompany groupRegulatory newsEuronext growth parisExtraordinary general meetingGeneral meetingGeneral meetings

Onxeo S A : Onxeo Announces its Financial Agenda for 2023

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX) (Paris:ALONX), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting

France generalOnis onxeoOnxeo sa euronextNicolas fossiezNicolas merigeauCompany groupRegulatory newsEuronext growth paris

ONXEO Provides Update on the Development Program For Its First-in-class Drug Candidate AsiDNATM

ONXEO Provides Update on the Development Program For Its First-in-class Drug Candidate AsiDNATM
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan antonioFrance generalShefali agarwalArthur rouillNicolas fossiezOnxeo sa euronextInstitut curieCompany groupEuronext growth parisNext oncology sanGustave roussy cancer campusGrand parisEuronext parisStrategic communication

Onxeo S A : ONXEO Provides Update on the Development Program For Its First-in-class Drug Candidate AsiDNATM

Phase 1b/2 trial of AsiDNATM in combination with olaparib initiated in the United States in recurrent ovarian, breast and metastatic castration-resistant prostate cancer Phase 1b/2 trial (REVOCAN)

United statesSan antonioFrance generalShefali agarwalArthur rouillNicolas fossiezOnxeo sa euronextInstitut curieCompany groupEuronext growth parisNext oncology sanGustave roussy cancer campusGrand parisEuronext paris

ONXEO Provides Update on the Development Program For Its First-in-class Drug Candidate AsiDNATM

ONXEO Provides Update on the Development Program For Its First-in-class Drug Candidate AsiDNATM
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesFrance generalOnxeo sa euronextRegulatory newsEuronext growth parisNext oncology san